At a dinner symposium at Le Méridien Kuala Lumpur, Professor Dato’ Prepageran Narayanan presented the data concerning allergic rhinitis (AR) in Malaysia, and he discussed the role of intranasal corticosteroids (INCSs) in managing AR.
Prof. Giuseppe Mancia, Prof. Jong-Won Ha, Prof. Lin Jiunn-Lee, 20180711100146
Hypertension guidelines diﬀer in their recommendation to use beta-blockers as ﬁrst-line agents. At a Menarini-sponsored symposium held during the Asian Paciﬁc Society of Cardiology Congress 2018 in Taipei, Taiwan, Professor Giuseppe Mancia from the University of Milano-Bicocca in Milan, Italy and Professor Jong-Won Ha from the Yonsei University College of Medicine in Seoul, Korea discussed the rationale behind these recommendations, and reviewed the role of beta-blockers in hypertension management, particularly the role of vasodilatory beta-blocker nebivolol (Nebilet®, Menarini). Professor Lin Jiunn-Lee, APSC 2018 chairman and president of the Taiwan Society of Cardiology, chaired the symposium.
Airway diseases – such as chronic obstructive pulmonary disease and obstructive sleep apnoea – have a significant impact on one’s health, quality of life and daily functioning. This article discusses how technological advancements in non-invasive ventilation and home sleep testing systems help to improve patient care and outcomes.
Literature suggests that IPF is either the first or second most common interstitial lung disease (ILD) in pulmonology practice, with prevalence ranging from 17–86%. At the recent 3rd Respiratory Forum organized by Boehringer Ingelheim, Dr Felix Chua shared his insights into the importance of advancing the treatment paradigm of IPF, and the role of nintedanib (OFEV®) in its management.
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
At a GlaxoSmithKline-sponsored symposium during the Malaysian Thoracic Society Annual Congress 2017, Dr Celeste Mae Lardizabal-Campomanes presented on three key strategies of optimizing asthma treatment.
New therapies that specifically target inflammatory pathways or aberrant physiology in severe asthma offer substantial opportunities for effective treatment. Some of these therapies are available under specialist referral, and others are available in the context of clinical trials.